clinical trial · NCT03744910
Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients
CSL Behring·phase3·terminated·n = 194
Antibody-mediated RejectionClazakizumabPhysiologic saline solution
brief summary
This trial investigates the efficacy and safety of clazakizumab \[an anti-interleukin (IL)-6 monoclonal antibody (mAb)\] for the treatment of CABMR in recipients of a kidney transplant.
started
Oct 14, 2019
primary completion
Apr 8, 2024
completion
Apr 8, 2024
last updated
Jul 23, 2025
official title
A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-mediated Rejection in Kidney Transplant Recipients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol